How does cosentyx affect mmr vaccine efficacy?

How does cosentyx affect MMR vaccine efficacy?

Cosentyx contains secukinumab, a monoclonal antibody that targets interleukin-17A. By blocking IL-17A, it suppresses parts of the immune system involved in inflammatory conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. This suppression can alter how the body responds to vaccines.

Does Cosentyx reduce MMR vaccine response?

Cosentyx does not appear to impair MMR vaccine efficacy in any measured way. Clinical data show patients taking secukinumab still produce adequate antibody responses to non-live vaccines such as tetanus, influenza, and pneumococcal vaccines. Because MMR is a live attenuated vaccine, official guidelines advise caution rather than outright contraindication.

What happens if you receive MMR vaccine while on Cosentyx?

The risk of vaccine-derived infection remains low but cannot be ruled out. Patients who already have immunity from prior MMR doses or infection do not receive live vaccines under immunosuppression. New recipients of MMR while on Cosentyx should discuss timing with their doctor, usually with a four-week window before or after stopping therapy.

Why are companies challenging this patent?

Secukinumab’s basic compound patent expires in 2025. Companies are pursuing biosimilar versions and patent challenges focused mainly on manufacturing processes and formulation patents that extend exclusivity beyond 2025.